4-(4-Hydroxyphenyl)-2,2-dimethyl-4-oxobutanoic acid | 1367309-31-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(4-Hydroxyphenyl)-2,2-dimethyl-4-oxobutanoic acid
• CAS: 1367309-31-6
• 化学式: C₁₂H₁₄O₄
• 分子量: 222.241
• InChiKey: QUZSKACADDWSNJ-UHFFFAOYSA-N

物化性质

• 沸点：
  448.8±25.0 °C(Predicted)
• 密度：
  1.234±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-Hydroxyphenyl)-2,2-dimethyl-4-oxobutanoic acid 在 硫酸 、 potassium carbonate 、 potassium iodide 、 肼 作用下， 以 异丙醇 、 乙腈 为溶剂， 生成 (R)-4,4-dimethyl-6-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)-phenyl)-4,5-dihydropyridazin-3(2H)-one
  参考文献：
  名称：

  4,5-Dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists

  摘要：

  H3R structure-activity relationships for a new class of 4,5-dihydropyridazin-3-one H3R antagonists/inverse agonists are disclosed. Modification of the 4,5-dihydropyridazinone moiety to block in vivo metabolism identified 4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one 22 as a lead candidate demonstrating potent in vivo functional H3R antagonism in the rat dipsogenia model and robust wake promoting activity in the rat EEG/EMG model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.037
• 作为产物：
  描述：

  2,2-二甲基琥珀酸酐 在 氢溴酸 作用下， 以 四氢呋喃 为溶剂， 生成 4-(4-Hydroxyphenyl)-2,2-dimethyl-4-oxobutanoic acid
  参考文献：
  名称：

  4,5-Dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists

  摘要：

  H3R structure-activity relationships for a new class of 4,5-dihydropyridazin-3-one H3R antagonists/inverse agonists are disclosed. Modification of the 4,5-dihydropyridazinone moiety to block in vivo metabolism identified 4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one 22 as a lead candidate demonstrating potent in vivo functional H3R antagonism in the rat dipsogenia model and robust wake promoting activity in the rat EEG/EMG model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.037

文献信息

• Leukotriene antagonists
  申请人：MERCK FROSST CANADA INC.

  公开号：EP0252639A1

  公开（公告）日：1988-01-13

  Compounds of the Formulae: and are antagonists of leukotrienes of C4, D4 and E4, the slow reacting substance of anaphylaxis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.

  这些化合物可用作抗哮喘、抗过敏、抗炎和细胞保护剂。
• Leukotriene antagonists, their production, and compositions containing them
  申请人：MERCK FROSST CANADA INC.

  公开号：EP0104885B1

  公开（公告）日：1986-06-04
• US5135940A
  申请人：——

  公开号：US5135940A

  公开（公告）日：1992-08-04
• 4,5-Dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists
  作者：Robert L. Hudkins、Lisa D. Aimone、Reddeppa reddy Dandu、Derek Dunn、John A. Gruner、Zeqi Huang、Kurt A. Josef、Jacquelyn A. Lyons、Joanne R. Mathiasen、Ming Tao、Allison L. Zulli、Rita Raddatz

  DOI：10.1016/j.bmcl.2011.11.037

  日期：2012.1

  H3R structure-activity relationships for a new class of 4,5-dihydropyridazin-3-one H3R antagonists/inverse agonists are disclosed. Modification of the 4,5-dihydropyridazinone moiety to block in vivo metabolism identified 4,4-dimethyl-6-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one 22 as a lead candidate demonstrating potent in vivo functional H3R antagonism in the rat dipsogenia model and robust wake promoting activity in the rat EEG/EMG model. (C) 2011 Elsevier Ltd. All rights reserved.